Recently, immune checkpoint inhibitors (ICIs) therapy has become a promising therapeutic
strategy with encouraging therapeutic outcomes due to their durable anti-tumor effects …

Abnormal vasculature is one of the most conspicuous traits of tumor tissue, largely
contributing to tumor immune evasion. The deregulation mainly arises from the potentiated …

Background In a single-group, phase 1b trial, avelumab plus axitinib resulted in objective
responses in patients with advanced renal-cell carcinoma. This phase 3 trial involving …

Over the past several decades, mRNA vaccines have evolved from a theoretical concept to a
clinical reality. These vaccines offer several advantages over traditional vaccine techniques …

Immunotherapy has emerged as a major therapeutic modality in oncology. Currently,
however, the majority of patients with cancer do not derive benefit from these treatments …

Purpose: This study assessed the safety and efficacy of SHR-1210 (anti-PD-1 antibody) and
apatinib (VEGFR2 inhibitor) as combination therapy in patients with advanced …

Advances in cancer immunity have promoted a major breakthrough in the field of cancer
therapy. This is mainly associated with the successful development of immune checkpoint …

Over the past 12 years, medical treatment for renal cell carcinoma (RCC) has transitioned
from a nonspecific immune approach (in the cytokine era), to targeted therapy against …

Over the past 25 years, research in cancer therapeutics has largely focused on two distinct
lines of enquiry. In one approach, efforts to understand the underlying cell-autonomous …

Renal cell carcinoma (RCC) is the most common form of kidney cancer. It is categorized into
various subtypes, with clear cell RCC (ccRCC) representing about 85% of all RCC tumors …